Spyre Therapeutics (SYRE) Net Cash Flow (2015 - 2026)

Spyre Therapeutics has reported Net Cash Flow for 12 years, with the latest figure at $11.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 128.01% year-over-year to $11.5 million; the trailing twelve-month figure through Mar 2026 stood at $48.7 million (up 127.14% YoY), and the FY2025 full-year result was -$3.7 million, up 96.29% from the prior year.
• Net Cash Flow for Q1 2026 stood at $11.5 million, down from $20.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $200.1 million in Q2 2023, with the low at -$182.4 million in Q2 2024.
• Historically, Net Cash Flow has averaged $4.7 million across 5 years, with a median of $11.5 million in 2026.
• Annual changes were most pronounced in 2023 — Net Cash Flow plunged 11226.75% — and 2024, when it jumped 30582.54%.
• Spyre Therapeutics' Net Cash Flow stood at -$4.1 million in 2022, then surged by 2445.66% to $97.3 million in 2023, then tumbled by 81.65% to $17.9 million in 2024, then rose by 16.61% to $20.8 million in 2025, then tumbled by 44.95% to $11.5 million in 2026.
• The last three Net Cash Flow figures came in at $11.5 million (Q1 2026), $20.8 million (Q4 2025), and -$16.8 million (Q3 2025), per Business Quant data.